Wed, 23 May 2012 12:02:37 GMT
Insmed Incorporated Begins Screening Patients For TARGET-NTM US Clinical Trial ...MarketWatch (press release)Patients will continue with their antibiotic regimen, and receive additionally, either ARIKACE 560 mg or placebo, delivered once daily via an optimized, investigational eFlow® Nebulizer System (PARI Pharma GmbH). Primary efficacy endpoint will be ...and more »Wed, 23 May 2012 16:57:19 GMT
Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical ...Sacramento BeePatients will continue with their antibiotic regimen, and receive additionally, either ARIKACE 560 mg or placebo, delivered once daily via an optimized, investigational eFlow® Nebulizer System (PARI Pharma GmbH). Primary efficacy endpoint will be ...and more »